CAS No 1211441-98-3 RIBOCICLIB Pharmaceutical Intermediates
overview
RIBOCICLIB, also known as LEE011, is a selective cell cycle-dependent kinase 4 and 6 (CDK4/6) inhibitor, mainly used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.
By inhibiting CDK4/6, RIBOCICLIB can effectively disrupt the cell cycle and thus inhibit tumor cell proliferation. This makes it an important component of combination therapy for advanced breast cancer, providing patients with a valuable treatment option that can improve efficacy and prolong survival.
RIBOCICLIB is often used in combination with aromatase inhibitors or other hormonal therapies to enhance the therapeutic effect.
Physical and chemical properties
- Solubility: Soluble in dimethyl sulfoxide (DMSO) and methanol, slightly soluble in water, easy to prepare into various dosage forms.
- Melting point: approx. 150-155 °C
- Stability: RIBOCICLIB exhibits good stability under recommended storage conditions, ensuring longer shelf life and reliability in therapeutic applications.
These properties make RIBOCICLIB suitable for formulating a wide range of drug products, including tablets and oral solutions.
1. Targeted Therapy: RIBOCICLIB provides a targeted approach to cancer treatment by specifically inhibiting CDK4/6, which plays a key role in cell cycle regulation. This targeted action minimizes damage to normal cells and thus reduces side effects compared to traditional chemotherapy.
2. Efficacy of Combination Therapy: Clinical studies have shown that RIBOCICLIB, when used in combination with aromatase inhibitors or other hormonal therapies, can significantly improve progression-free survival in patients with HR+/HER2- breast cancer.
3. Regulatory Compliance: Our RIBOCICLIB is manufactured in accordance with international pharmaceutical standards, ensuring that it meets the strict requirements set by health authorities.
4. Research and Development Support: We provide comprehensive technical support and documentation to assist researchers and pharmaceutical companies in the development process.
As a production and trading integrated factory, we are committed to providing customers with high-quality RIBOCICLIB. Our dedication to quality is reflected in our advanced manufacturing process and strict quality control measures.
- Expertise: Our dedicated team of professionals is dedicated to research and development, ensuring we are always at the forefront of pharmaceutical innovation.
- Customer-centric approach: We prioritize our customers' needs, providing customized solutions and responsive customer service to support their specific requirements.
- Sustainability: We are committed to using sustainable practices in our manufacturing process, ensuring minimal impact on the environment while maintaining product quality.
In conclusion, RIBOCICLIB is an important pharmaceutical ingredient that offers numerous benefits in the treatment of hormone receptor-positive breast cancer. With our comprehensive production capabilities, high quality standards, and commitment to customer satisfaction, we are your ideal partner in the pharmaceutical industry.
Choose our RIBOCICLIB for your formulation and experience the difference in quality and efficacy.For inquiries or to place an order, please contact us today!